Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma

Abstract

Melflufen plus dexamethasone showed clinically meaningful efficacy and a manageable safety profile in patients with heavily pretreated RRMM, including those with triple-class-refractory and extramedullary disease.